FR2843881B1 - Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) - Google Patents

Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)

Info

Publication number
FR2843881B1
FR2843881B1 FR0210847A FR0210847A FR2843881B1 FR 2843881 B1 FR2843881 B1 FR 2843881B1 FR 0210847 A FR0210847 A FR 0210847A FR 0210847 A FR0210847 A FR 0210847A FR 2843881 B1 FR2843881 B1 FR 2843881B1
Authority
FR
France
Prior art keywords
microcapsules
principle
active
pharmaceutical formulation
aqueous suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0210847A
Other languages
English (en)
Other versions
FR2843881A1 (fr
Inventor
Catherine Castan
Florence Guimberteau
Remi Meyrueix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flamel Technologies SA
Original Assignee
Flamel Technologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0210847A priority Critical patent/FR2843881B1/fr
Application filed by Flamel Technologies SA filed Critical Flamel Technologies SA
Priority to JP2003581758A priority patent/JP4732696B2/ja
Priority to US10/510,643 priority patent/US7906145B2/en
Priority to ES03745832T priority patent/ES2320438T7/es
Priority to DE60325709T priority patent/DE60325709D1/de
Priority to PCT/FR2003/001096 priority patent/WO2003084518A2/fr
Priority to AT03745832T priority patent/ATE419840T1/de
Priority to BRPI0309142A priority patent/BRPI0309142C1/pt
Priority to KR1020047016079A priority patent/KR101061351B1/ko
Priority to CA2480826A priority patent/CA2480826C/fr
Priority to CNB038105284A priority patent/CN100553625C/zh
Priority to BR122013000700A priority patent/BR122013000700B8/pt
Priority to AU2003246792A priority patent/AU2003246792B2/en
Priority to MXPA04009968A priority patent/MXPA04009968A/es
Priority to EP03745832A priority patent/EP1492511B3/fr
Priority to IL16422203A priority patent/IL164222A0/xx
Priority to PT03745832T priority patent/PT1492511E/pt
Publication of FR2843881A1 publication Critical patent/FR2843881A1/fr
Priority to IL164222A priority patent/IL164222A/en
Priority to HK05111660.1A priority patent/HK1079448A1/xx
Publication of FR2843881B1 publication Critical patent/FR2843881B1/fr
Application granted granted Critical
Priority to US13/014,137 priority patent/US10004693B2/en
Priority to US14/848,603 priority patent/US20150374635A1/en
Priority to US14/848,699 priority patent/US9814684B2/en
Priority to US15/625,727 priority patent/US20170281558A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
FR0210847A 2002-04-09 2002-09-02 Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) Expired - Fee Related FR2843881B1 (fr)

Priority Applications (23)

Application Number Priority Date Filing Date Title
FR0210847A FR2843881B1 (fr) 2002-09-02 2002-09-02 Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
ES03745832T ES2320438T7 (es) 2002-04-09 2003-04-07 Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s)
MXPA04009968A MXPA04009968A (es) 2002-04-09 2003-04-07 Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
DE60325709T DE60325709D1 (de) 2002-04-09 2003-04-07 Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
PCT/FR2003/001096 WO2003084518A2 (fr) 2002-04-09 2003-04-07 Suspension orale de microcapsules de principes actifs
AT03745832T ATE419840T1 (de) 2002-04-09 2003-04-07 Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
BRPI0309142A BRPI0309142C1 (pt) 2002-04-09 2003-04-07 suspensão de microcápsulas em uma fase líquida aquosa, que permite a liberação modificada de pelo menos um princípio ativo com exclusão da amoxicilina e que é destinada a ser administrada por via oral
KR1020047016079A KR101061351B1 (ko) 2002-04-09 2003-04-07 활성 성분 마이크로캡슐의 경구 현탁액
CA2480826A CA2480826C (fr) 2002-04-09 2003-04-07 Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
CNB038105284A CN100553625C (zh) 2002-04-09 2003-04-07 活性成分微囊的口服混悬液
BR122013000700A BR122013000700B8 (pt) 2002-04-09 2003-04-07 "suspensão microcápsulas em uma fase líquida aquasa"
US10/510,643 US7906145B2 (en) 2002-04-09 2003-04-07 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
JP2003581758A JP4732696B2 (ja) 2002-04-09 2003-04-07 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
EP03745832A EP1492511B3 (fr) 2002-04-09 2003-04-07 Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
AU2003246792A AU2003246792B2 (en) 2002-04-09 2003-04-07 Oral suspension of active principle microcapsules
PT03745832T PT1492511E (pt) 2002-04-09 2003-04-07 Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
IL16422203A IL164222A0 (en) 2002-04-09 2003-04-07 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
IL164222A IL164222A (en) 2002-04-09 2004-09-22 Oral pharmacological formulation in the form of an aqueous suspension for the adjusted release of active ingredients
HK05111660.1A HK1079448A1 (en) 2002-04-09 2005-12-17 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US13/014,137 US10004693B2 (en) 2002-04-09 2011-01-26 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US14/848,603 US20150374635A1 (en) 2002-04-09 2015-09-09 Oral pharmaceutical formulation in the form of an aqueous suspension of microcapsules for the modified release of active principle(s)
US14/848,699 US9814684B2 (en) 2002-04-09 2015-09-09 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US15/625,727 US20170281558A1 (en) 2002-04-09 2017-06-16 Oral pharmaceutical formulation in the form of an aqueous suspension of microcapsules for the modified release of active principle(s).

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0210847A FR2843881B1 (fr) 2002-09-02 2002-09-02 Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)

Publications (2)

Publication Number Publication Date
FR2843881A1 FR2843881A1 (fr) 2004-03-05
FR2843881B1 true FR2843881B1 (fr) 2006-06-02

Family

ID=31503048

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0210847A Expired - Fee Related FR2843881B1 (fr) 2002-04-09 2002-09-02 Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)

Country Status (1)

Country Link
FR (1) FR2843881B1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007833A1 (fr) * 1986-06-20 1987-12-30 Shacknai Jonah Medicament a avaler a liberation entretenue
IT1227899B (it) * 1988-12-23 1991-05-14 Poli Ind Chimica Spa Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
IT1256651B (it) * 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
FI922107A0 (fi) * 1991-05-10 1992-05-08 Faulding F H & Co Ltd Mikrokapselkomposition och foerfarande.
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation

Also Published As

Publication number Publication date
FR2843881A1 (fr) 2004-03-05

Similar Documents

Publication Publication Date Title
GT199800113A (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
IL166431A0 (en) Microcapsules with modified release of active principles with low solubility for oral delivery
FR2830447B1 (fr) Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
DE60100186D1 (de) Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung
BRPI0407430A (pt) Sal do ácido benzenossulfÈnico com clopidogrel, processos para preparação do mesmo, e para purificação de clopidogrel, uso de um sal, formulação farmacêutica, partìculas de substância ativa, uso de partìculas de substância ativa, e, processo para preparação de partìculas de substância ativa
PT2025670E (pt) Utiliza??o de derivados do ?cido 3-feniltio-1h-indole-1-ac?tico como moduladores da actividade dos receptores crth2
HUP0203028A2 (hu) Tolterodint tartalmazó gyógyszerkészítmény és alkalmazása
NO20033564D0 (no) Ny formulering med modifisert frigivningsvirkning
ECSP044974A (es) Formulación de suspensión oral estabilizada
FR2915683B1 (fr) Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
ATE388703T1 (de) Pharmazeutische formulierung des telmisartan natriumsalzes
NO20020611D0 (no) Ektoparasittiske vandige suspensjonsformuleringer av spinosyrer
YU59201A (sh) Matrica koja se može direktno komprimovati, za kontrolisano oslobadjanje pojedinačnih dnevnih doza klaritromicina
NO20043832L (no) Oral fast losningsformulering av en darlig vannloselig aktiv substans
ECSP055998A (es) Composición farmacéutica que comprende ácido 5-metil-2-2'-(cloro-6'-fluoroanilino)fenilacético
FR2845597B1 (fr) Formulation orale seche contenant de la diosmine sous forme pharmaceutique de comprime a croquer
FR2843881B1 (fr) Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
DE602004001969D1 (de) Orale pharmazeutische Zusammensetzung und Verfahren zu ihrer Herstellung
FR2843880B1 (fr) Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
DE60319983D1 (de) Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan
NO20043084L (no) 3-fenyl-2-arylalkyltiopropionsyre derivater som selektive agnoister av PPAR-ALPHA
PT1179342E (pt) Composicoes medicinais de libertacao imediata para utilizacao oral
MA29560B1 (fr) Formulation a liberation prolongee de principes actifs de medicaments
NO20033704D0 (no) Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20130531